miRagen Therapeutics

71 articles with miRagen Therapeutics

• 

  RNAi: The Monoclonal Antibody of the 2020s?

  8/29/2018

  There’s been another milestone in the history of biotech: The world’s first RNAi gene-silencing drug, Alnylam Pharmaceuticals’ Onpattro, got approved on August 10. That makes 2018 a landmark year. But another year—2014—may prove just as influential for the field and how it develops.
• 

  Navitor Appoints New CEO

  8/3/2018

  Navitor Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced that Thomas E. Hughes will be the company’s new chief executive officer.

• miRagen Therapeutics Prices Public Offering of Common Stock

  2/9/2018

  In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock on the same terms and conditions.

• miRagen Therapeutics Announces Proposed Public Offering of Common Stock

  2/5/2018

  All of the common stock is being offered by miRagen

• miRagen Therapeutics Presents New Data from Phase I Clinical Trial of MRG-106 in Mycosis Fungoides at the T-Cell Lymphoma Forum

  2/2/2018

  The data will be presented today, February 2, 2018, at the 10th Annual T-cell Lymphoma Forum in La Jolla, California.

• 

  Why This Mostly-Unheard of Colorado Biotech Could Hit $1B in Revenue by 2025

  1/16/2018

  Leah Rush Cann, an analyst with Oppenheimer, launched coverage of this biotech citing the possibility it could exceed $1.2B in revenue by 2025.

• miRagen Therapeutics Expands Board of Directors With Appointment of Arlene Morris

  1/5/2018

  Her appointment increases miRagen’s Board from seven directors to eight directors.

• miRagen Therapeutics Presents New Interim Clinical Data Expanding on Previous Data Suggesting Positive Impact From Systemically Administered MRG-106 on Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma

  12/12/2017

  The data are being presented at the 2017 American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia, by Christiane Querfeld, M.D., Ph.D., Chief of the Division of Dermatology, and Director, Cutaneous Lymphoma Program at the City of Hope in Duarte, California.

• miRagen Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update

  11/9/2017

  Revenue was $1.6 million for the third quarter of 2017, compared to $0.9 million for the third quarter of the prior year.

• miRagen Presents New Clinical Data Suggesting Positive Impact From Systemically Administered MRG-106 On Mycosis Fungoides Form Of Cutaneous T-Cell Lymphoma At EORTC Global Task Force Meeting

  10/13/2017

• miRagen Presents New MRG-201 Preclinical Data For Inhaled Microrna-29 Mimic Targeting Pulmonary Fibrosis

  9/12/2017

• miRagen Reports Second Quarter 2017 Financial Results And Provides Corporate Update

  8/14/2017

• miRagen To Announce Second Quarter 2017 Financial Results And Host Webcast Conference Call On August 11, 2017

  8/1/2017

• miRagen To Ring The Nasdaq Stock Market Closing Bell

  7/21/2017

• miRagen To Present MRG-106 Phase I Clinical Trial Data At The International Conference On Malignant Lymphoma

  6/8/2017

• miRagen Receives EU Orphan Medicinal Product Designation For MRG-106 For The Treatment Of Cutaneous T-Cell Lymphoma

  5/24/2017

• miRagen To Present New Clinical Trial Data For MRG-106, An Oligonucleotide Therapeutic Targeting Microrna-155, At The ASCO Annual Meeting

  5/18/2017

• miRagen Reports First Quarter 2017 Financial Results And Provides Corporate Update

  5/11/2017

• Servier And miRagen Extend Collaboration For The Research, Development And Commercialization Of Microrna-Targeting Therapeutics

  5/3/2017

• miRagen To Host Conference Call Discussing First Quarter 2017 Corporate Update And Financial Results

  5/3/2017